JP2008502698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008502698A5 JP2008502698A5 JP2007516693A JP2007516693A JP2008502698A5 JP 2008502698 A5 JP2008502698 A5 JP 2008502698A5 JP 2007516693 A JP2007516693 A JP 2007516693A JP 2007516693 A JP2007516693 A JP 2007516693A JP 2008502698 A5 JP2008502698 A5 JP 2008502698A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- albuterol
- dosage form
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 239000002552 dosage form Substances 0.000 claims 13
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 claims 11
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 claims 11
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 11
- 239000004036 potassium channel stimulating agent Substances 0.000 claims 11
- 229960002052 salbutamol Drugs 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 10
- 208000019693 Lung disease Diseases 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 208000023504 respiratory system disease Diseases 0.000 claims 6
- 208000006673 asthma Diseases 0.000 claims 5
- 230000000414 obstructive effect Effects 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- CTQURVKMWHDOKO-UHFFFAOYSA-N Dehydrosoyasaponin I Natural products CC1OC(OC2C(O)C(O)C(CO)OC2OC3C(O)C(O)C(OC3OC4CCC5(C)C(CCC6(C)C5CC=C7C8CC(C)(C)CC(=O)C8(C)CCC67C)C4(C)C=O)C(=O)O)C(O)C(O)C1O CTQURVKMWHDOKO-UHFFFAOYSA-N 0.000 claims 4
- CROUPKILZUPLQA-ITVSDQETSA-N Dehydrosoyasaponin I Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H](O[C@@H]([C@@H](O)[C@@H]2O)C(O)=O)O[C@@H]2[C@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(CC[C@@]6(C)C(=O)CC(C)(C)C[C@H]6C5=CC4)C)(C)CC3)(C)CC2)(C)CO)O[C@H](CO)[C@H](O)[C@@H]1O CROUPKILZUPLQA-ITVSDQETSA-N 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 4
- 206010006482 Bronchospasm Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims 2
- ZSUFQZNGDIXQAD-CABCVRRESA-N 1-[(3s,4r)-3-hydroxy-2,2-dimethyl-6-(1,1,2,2,2-pentafluoroethyl)-3,4-dihydrochromen-4-yl]piperidin-2-one Chemical compound N1([C@@H]2C3=CC(=CC=C3OC([C@H]2O)(C)C)C(F)(F)C(F)(F)F)CCCCC1=O ZSUFQZNGDIXQAD-CABCVRRESA-N 0.000 claims 2
- KFFJPIQLAPHYBF-UHFFFAOYSA-N Azukisaponin V Natural products COC(=O)C1OC(OC2CCC3(C)C(CCC4(C)C3CC=C5C6CC(C)(C)CC(O)C6(O)CCC45C)C2(C)CO)C(OC7OC(CO)C(O)C(O)C7OC8OC(C)C(O)C(O)C8O)C(O)C1O KFFJPIQLAPHYBF-UHFFFAOYSA-N 0.000 claims 2
- 208000004657 Exercise-Induced Asthma Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- -1 NS 004 Chemical compound 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- JFHRJMPZZYINAI-UHFFFAOYSA-N Soyasaponin I Natural products CC1OC(OC2C(O)C(O)C(CO)OC2OC3C(O)C(O)C(CO)OC3OC4CCC5(C)C(CCC6(C)C5CC=C7C8CC(C)(C)CC(O)C8(C)CCC67C)C4(C)CO)C(O)C(O)C1O JFHRJMPZZYINAI-UHFFFAOYSA-N 0.000 claims 2
- UZUYQJHHUUDLDJ-UHFFFAOYSA-N Soyasaponin III Natural products CC1(C)CC(O)C2(C)CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(C)(CO)C5CCC34C)C2C1 UZUYQJHHUUDLDJ-UHFFFAOYSA-N 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 229940071648 metered dose inhaler Drugs 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 230000002441 reversible effect Effects 0.000 claims 2
- PTDAHAWQAGSZDD-IOVCITQVSA-N soyasaponin I Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H](O[C@@H]([C@@H](O)[C@@H]2O)C(O)=O)O[C@@H]2[C@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(CC[C@@]6(C)[C@H](O)CC(C)(C)C[C@H]6C5=CC4)C)(C)CC3)(C)CC2)(C)CO)O[C@H](CO)[C@H](O)[C@@H]1O PTDAHAWQAGSZDD-IOVCITQVSA-N 0.000 claims 2
- OKIHRVKXRCAJFQ-AHBDIROXSA-N soyasaponin III Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@]1(CO)C)C)(C)CC[C@@]1(C)[C@H](O)CC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O OKIHRVKXRCAJFQ-AHBDIROXSA-N 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010003598 Atelectasis Diseases 0.000 claims 1
- 208000009079 Bronchial Spasm Diseases 0.000 claims 1
- 208000014181 Bronchial disease Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 201000003453 lung abscess Diseases 0.000 claims 1
- 238000009115 maintenance therapy Methods 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 201000004193 respiratory failure Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57882704P | 2004-06-14 | 2004-06-14 | |
| US59902704P | 2004-08-06 | 2004-08-06 | |
| US60729004P | 2004-09-07 | 2004-09-07 | |
| PCT/US2005/021171 WO2005123071A1 (en) | 2004-06-14 | 2005-06-14 | Methods of using albuterol and calcium activated potassium channel openers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008502698A JP2008502698A (ja) | 2008-01-31 |
| JP2008502698A5 true JP2008502698A5 (enExample) | 2008-07-31 |
Family
ID=35509445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007516693A Abandoned JP2008502698A (ja) | 2004-06-14 | 2005-06-14 | アルブテロール、及びカルシウム活性化カリウムチャネルオープナーの使用方法。 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090035224A1 (enExample) |
| EP (1) | EP1773325A4 (enExample) |
| JP (1) | JP2008502698A (enExample) |
| AU (1) | AU2005254096A1 (enExample) |
| CA (1) | CA2570386A1 (enExample) |
| WO (1) | WO2005123071A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004015788D1 (de) * | 2004-08-19 | 2008-09-25 | Rottapharm Spa | Verwendung von Phenylbenzamide-derivaten zur Behandlung von chronisch-obstruktiver Lungenerkrankung (COPD) |
| CA2635649A1 (en) * | 2006-01-06 | 2007-07-12 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and andolast |
| EP2054057B1 (en) | 2006-07-31 | 2011-04-27 | Rottapharm S.p.A. | Combination andolast/glucocorticoids |
| JP6211380B2 (ja) * | 2012-10-17 | 2017-10-11 | 丸善製薬株式会社 | Ｔｉｅ２活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤 |
| JP2013056925A (ja) * | 2012-11-21 | 2013-03-28 | Rottapharm Spa | アンドラスト／グルココルチコイドの併用 |
| CN112535668B (zh) * | 2020-10-29 | 2023-08-18 | 苏州君宁新药开发中心有限公司 | 一种左旋硫酸沙丁胺醇颗粒剂及其用途 |
| CN113476428B (zh) * | 2021-01-28 | 2022-03-29 | 朗天药业(湖北)有限公司 | 一种吸入用硫酸沙丁胺醇溶液及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0509036T3 (da) * | 1990-01-05 | 1996-07-29 | Sepracor Inc | Optisk ren R(-)-albuterol til behandling af astma |
| US5200422A (en) * | 1990-09-24 | 1993-04-06 | Neurosearch A/S | Benzimidazole derivatives, their preparation and use |
| US5637470A (en) * | 1994-05-13 | 1997-06-10 | Merck & Co., Inc. | Screening array using cells expressing recombinant α and β subunits of the mammalian large-conductance (maxi-K) potassium channel |
| PT896821E (pt) * | 1997-08-08 | 2003-08-29 | Rotta Research Lab | Uma nova composicao farmaceutica para inalacao que contem cr 2039 (andolast) |
| HUP0103160A3 (en) * | 1998-08-26 | 2002-11-28 | Smithkline Beecham Corp | Pharmaceutical compositions for treating pulmonary diseases containing pde4 inhibitor |
| US6656461B1 (en) * | 2000-02-29 | 2003-12-02 | The Trustees Of Columbia University In The City Of New York | Therapeutic treatment of chronic obstructive pulmonary disease |
| US7713964B2 (en) * | 2001-12-03 | 2010-05-11 | Wyeth Llc | Methods for treating asthmatic conditions |
| TWI271402B (en) * | 2002-10-15 | 2007-01-21 | Tanabe Seiyaku Co | Large conductance calcium-activated K channel opener |
| US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
-
2005
- 2005-06-14 EP EP05766071A patent/EP1773325A4/en not_active Withdrawn
- 2005-06-14 CA CA002570386A patent/CA2570386A1/en not_active Abandoned
- 2005-06-14 US US11/629,686 patent/US20090035224A1/en not_active Abandoned
- 2005-06-14 WO PCT/US2005/021171 patent/WO2005123071A1/en not_active Ceased
- 2005-06-14 JP JP2007516693A patent/JP2008502698A/ja not_active Abandoned
- 2005-06-14 AU AU2005254096A patent/AU2005254096A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130052T1 (hr) | Lijeäśenje respiratorne bolesti | |
| JP2013224331A5 (enExample) | ||
| EP2259773B1 (en) | Macrolide compositions having improved taste and stability | |
| ES2309705T3 (es) | Nueva combinacion de anticolinergico y beta-mimeticos para el tratamiento de enfermedades respiratorias. | |
| TWI758617B (zh) | 包含格隆銨鹽及茚達特羅鹽的氣霧劑藥物組合物、其製備方法與用途 | |
| JP2014518268A5 (enExample) | ||
| SI1991201T1 (en) | NEBULISED ANTIBIOTICS FOR INHALATION THERAPY | |
| JP2010508365A5 (enExample) | ||
| WO2005025540A3 (en) | Mucoactive agents for treating a pulmonary disease | |
| PT2315580E (pt) | Formulações farmacêuticas e métodos para o tratamento de infeções do trato respiratório | |
| KR20110091505A (ko) | Ｃｏｐｄ 및 기타 폐질환의 치료 방법 | |
| JP2008502699A5 (enExample) | ||
| CN102652017A (zh) | 协同抗病毒组合物及其应用 | |
| CN115768402A (zh) | 用于治疗急性肺损伤的5-氨基-2,3-二氢-1,4-酞嗪二酮 | |
| US20120076859A1 (en) | Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases | |
| JP2008513444A (ja) | リドカイン及び他の局所麻酔剤の標的運搬並びに咳そう及び咳の発作の処置のための方法 | |
| JP2008502698A5 (enExample) | ||
| JP2020516689A5 (enExample) | ||
| Dongare et al. | An overview of recently published patents on pulmonary drug delivery devices | |
| CA2813750A1 (en) | Method for treating cystic fibrosis with inhaled denufosol | |
| CA2701388C (en) | Calcium glycerophosphate for treating and preventing respiratory diseases or conditions | |
| Noseda et al. | Sympathomimetics in acute severe asthma: inhaled or parenteral, nebulizer or spacer? | |
| JP2013522295A5 (enExample) | ||
| KR20130140672A (ko) | 기침 치료용 카보네이트 유도체 | |
| WO2010009288A1 (en) | Compositions and uses of antiviral active pharmaceutical agents |